You just read:

Phase 3b Study Shows Significantly Less Bleeding with XARELTO® (rivaroxaban) Compared to Warfarin in People with Non-Valvular Atrial Fibrillation Following Percutaneous Coronary Intervention with Stenting

News provided by

Janssen Pharmaceuticals, Inc.

Nov 14, 2016, 11:45 ET